Literature DB >> 6751532

Review of etoposide single-agent activity.

H Schmoll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6751532     DOI： 10.1016/s0305-7372(82)80074-1

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.

Authors:  B A Ponder; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 3.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

Review 4.  Oral etoposide in lymphoma.

Authors:  F A Greco
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children's Cancer Group Study, CCG-9881.

Authors:  N L Kobrinsky; R J Packer; J M Boyett; P Stanley; T Shiminski-Maher; J C Allen; J H Garvin; D J Stewart; J L Finlay
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J M Dennery; R Belanger; J Gerin-Lajoie; V Montpetit; D Nundy; J Prior; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

7.  Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma.

Authors:  M A Pons; J L Finlay; R W Walker; D Puccetti; R J Packer; M McElwain
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.